Clostridium difficile in inflammatory bowel disease


Cite item

Full Text

Abstract

Aim. To study epidemiology and risk factors for Clostridium infection (CDI) associated with Clostridium difficile in patients with inflammatory bowel disease (IBD). Materials and methods. 1179 medical records were analyzed in a retrospective study of patients with IBD, of which 764 patients met the inclusion criteria. Patients were divided into 2 groups based on the presence of a preliminary diagnosis of CDI. Statistical analysis was carried out using Pearson Chi-square and two-sample t-test. Results. The incidence of CDI in patients with IBD was 17.3%, with the same prevalence in patients with Crohn's disease (CD) (n=53/40.1%) and ulcerative colitis (UC) (n=79/59.9%). The mean age of occurrence of CDI in patients with IBD was 37.8±12.9, 84.8% of infections were community-acquired and only 4.5% occurred in medical institutions. Only 21.2% of all patients with CDI had a history of antibiotic use, and 24.2% had previously used steroids. Long-term immunosuppressive therapy in patients with IBD has an impact on the development of CDI: among patients with CDI 45.5% long-term received azathioprine/6-mercaptopurine, in patients without IBD - 17.7% (p<0.001). 18% of patients with CDI had control of the disease with salicylate therapy, while 62% of patients without CDI achieved remission by taking salicylates (p<0.05). Conclusion. The prevalence of CDI in UC and CD is comparable (p=0.16). The study shows that patients with IBD are more sensitive to the development of CDI at a young age, while not having such traditional risk factors as recent hospitalization or antibiotic use. Patients with IBD with CDI in history often noted the ineffectiveness of therapy with salicylates, often require the assignment of biological therapy. IBD patients with CDI have a lower average albumin, and a higher activity of the inflammatory process.

About the authors

O V Knyazev

A.S. Loginov Moscow Clinical Scientific Center

д.м.н., зав. отд-нием воспалительных заболеваний кишечника Moscow, Russia

A V Kagramanova

A.S. Loginov Moscow Clinical Scientific Center

к.м.н., с.н.с. отд-ния патологии кишечника Moscow, Russia

M E Chernova

A.S. Loginov Moscow Clinical Scientific Center

к.м.н., врач-инфекционист Moscow, Russia

I A Korneeva

A.S. Loginov Moscow Clinical Scientific Center

врач-гастроэнтеролог отд-ния воспалительных заболеваний кишечника Moscow, Russia

A I Parfenov

A.S. Loginov Moscow Clinical Scientific Center

Email: asfold@mail.ru
д.м.н., проф., зав. отд. патологии кишечника ГБУЗ МКНЦ им. А.С. Логинова ДЗМ Moscow, Russia

References

  1. Magill S.S, Edwards J.R, Bamberg W, et al. Multistate point - prevalence survey of health care associated infections. New Eng J Med. 2014;370:1198-208.
  2. Salen P, Stankewicz H.A. Colitis, Pseudomembranous. StatPearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2018 Jan-2017 Dec 4.
  3. Tariq R, Singh S, Gupta A, Pardi D.S, Khanna S. Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta - analysis. JAMA Intern Med. 2017(Jun1);177(6):784-91. doi: 10.1001/jamainternmed.2017.0212
  4. Lessa F.C, Mu Y, Bamberg W.M, et al. Burden of Clostridium difficile infection in the United States. New Eng J Med. 2015;372(9):825-34.
  5. Miller B.A, Chen L.F, Sexton D.J, Anderson D.J. Comparison of the burdens of hospital - onset, healthcare facility - associated Clostridium difficile infection and of healthcare - associated infection due to methicillin - resistant Staphylococcus aureus in community hospitals. Infection Control and Hospital Epidemiology. 2011;32(4):387-90.
  6. Zimlichman E, Henderson D, Tamir O, et al. Health care associated infections: a meta - analysis of costs and financial impact on the US health care system. JAMA Int Med. 2013;173(22):2039-46.
  7. Bignardi G.E. Risk factors for Clostridium difficile infection. J Hosp Inf. 1998;40(1):1-15.
  8. Khannaand S, Pardi D.S. IBD:poor out comes after Clostridium difficile infection in IBD. Nat Rev Gastroenterol Hepatol. 2012;9(6):307-8.
  9. Ananthakrishnan A.N, Mc Ginley E.L, Binion D.G. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut. 2008;57(2):205-10.
  10. Ananthakrishnan A.N, Oxford E.C, Nguyen D.D, Sauk J, Yajnik V, Xavier RJ. Disclosures Genetic Risk Factors for Clostridium difficile Infection in Ulcerative Colitis. Aliment Pharmacol Ther. 2013;38(5):522-30.
  11. Khanna S, Pardi D.S. The growing incidence and severity of Clostridium difficile infectionin inpatient and outpatient settings. Exp Rev Gastroenterol Hepatol. 2010;4(4):409-16.
  12. Khanna S, Pardi D.S, Aronson S.L, et al. The epidemiology of community - acquired Clostridium difficile infection: a population - based study. Am J Gastroenterol. 2012;107(1):89-95.
  13. Cohen S.H, Gerding D.N, Johnsonetal S. Clinicalpractice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Health care Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infection Control and Hospital Epidemiology. 2010;31(5):431-55.
  14. Nguyen G.C, Kaplan G.G, Harris N.L, Brant S.R. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103(6):1443-50.
  15. Issa M, Vijayapal A, Graham M.B, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):345-51.
  16. Soler P, Nogareda F, Cano R. Rates of Clostridium difficile infection in patients discharged from Spanish hospitals, 1997-2005. Infection Control and Hospital Epidemiology. 2008;29(9):887-9.
  17. Burckhardt F, Friedrich A, Beier D, Eckmanns T. Clostridium difficile surveillance trends, Saxony, Germany. Emerg Infect Dis. 2008;14:691-92.
  18. Lucado J, Gould C, Elixhauser A. Clostridium difficile infections (CDI) in hospital stays, 2009: statistical brief №124, in Healthcare Cost and Utilization Project (HCUP) Statistical Briefs, Agency for Healthcare Research and Quality (US), Rockville (MD), 2006.
  19. Reveles K.R, Lee G.C, Boyd N.K, Frei C.R. Therisein Clostridium difficile infection incidence among hospitalized adults in the United States: 2001-2010. Am J Infect Control. 2014;42(10):1028-32.
  20. Wilcox M.H, Shetty N, Fawley W.N, et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping - based surveillance scheme in England. Clin Infect Dis. 2012;55(8):1056-63.
  21. Wilcox M.H, Mooney L, Bendall R, Settle C.D, Fawley W.N. A case - control study of community - associated Clostridium difficile infection. J Antimicrob Chemother. 2008;62(2):388-96.
  22. Kutty P.K, Woods C.W, Sena A.C, et al. Risk factors for and estimated incidence of community - associated Clostridium difficile infection, North Carolina, USA. Emerging Infectious Diseases. 2010;16:197-204.
  23. Lambert P.J, Dyck M, Thompson L.H, Hammond G.W. Population - based surveillance of Clostridium difficile infection in Manitoba, Canada, by using interim surveillance definitions. Infection Control and Hospital Epidemiology. 2009;30(10):945-51.
  24. Issa M, Ananthakrishnan A.N, Binion D.G. Clostridium difficile and inflammatory bowel disease. Inflammat Bowel Diseases. 2008;14(10):1432-42.
  25. Das R, Feuerstadt P, Brandt L.J. Glucocorticoids are associated with increased risk of short - term mortality in hospitalized patients with clostridium difficile - associated disease. Am J Gastroenterol. 2010;105(9):2040-9.
  26. Khanna S, Tosh P.K. A clinician’s primer on the role of the microbiome in human health and disease. Mayo Clinic Proceedings. 2014;89(1):107-14.
  27. Matsuoka K, Kanai T. The gut microbiota and inflammatory bowel disease. Seminars in Immunopathology. 2015;37(1):47-55.
  28. Schneeweiss S, Korzenik J, Solomon D.H, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Alimentary Pharmacol Therapeutics. 2009;30(3):253-64.
  29. Kariv R, Navaneethan U, Venkatesh P.G, Lopez R, Shen B. Impact of Clostridium difficile infection in patients with ulcerative colitis. J Crohn's & Colitis. 2011;5(1):34-40.
  30. Engel M.A, Neurath M.F. New pathophysiological insights and modern treatment of IBD. J Gastroenterol. 2010;45(6):571-83.
  31. Князев О.В., Парфенов А.И., Ручкина И.Н., Лазебник Л.Б., Сагынбаева В.Э. Иммунный ответ на биологическую терапию воспалительных заболеваний кишечника. Терапевтический архив. 2013;85(12):55-9.
  32. William Gillespie, Neil Marya, Julien Fahed, Gregory Leslie, Krunal Patel, David R. Cave. Clostridium difficile in Inflammatory Bowel Disease: A Retrospective Study. Gastroenterology Research and Practice Volume. 2017; Article ID 4803262:5. https://doi.org/10.1155/ 2017/4803262.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies